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Summary
 
The 4-1BB receptor is an inducible type I membrane protein and member of the tumor necro-
sis factor receptor (TNFR) superfamily that is rapidly expressed on the surface of CD4
 
1
 
 and
CD8
 
1
 
 T cells after antigen- or mitogen-induced activation. Cross-linking of 4-1BB and the T
cell receptor (TCR) on activated T cells has been shown to deliver a costimulatory signal to T
cells. Here, we expand upon previously published studies by demonstrating that CD8
 
1
 
 T cells
when compared with CD4
 
1
 
 T cells are preferentially responsive to both early activation events
and proliferative signals provided via the TCR and 4-1BB. In comparison, CD28-mediated
costimulatory signals appear to function in a reciprocal manner to those induced through 4-1BB
costimulation. In vivo examination of the effects of anti-4-1BB monoclonal antibodies (mAbs)
on antigen-induced T cell activation have shown that the administration of epitope-specific
anti-4-1BB mAbs amplified the generation of H-2
 
d
 
–specific cytotoxic T cells in a murine
model of acute graft versus host disease (GVHD) and enhanced the rapidity of cardiac allograft
or skin transplant rejection in mice. Cytokine analysis of in vitro activated CD4
 
1
 
 and CD8
 
1
 
T cells revealed that anti-4-1BB costimulation markedly enhanced interferon-
 
g
 
 production by
CD8
 
1
 
 T cells and that anti-4-1BB mediated proliferation of CD8
 
1
 
 T cells appears to be IL-2
independent. The results of these studies suggest that regulatory signals delivered by the 4-1BB
receptor play an important role in the regulation of cytotoxic T cells in cellular immune re-
sponses to antigen.
 
4
 
-1BB is a recently cloned pan T cell activation antigen
and member of the low affinity nerve growth factor re-
ceptor/tumor necrosis factor receptor (NGFR/TNFR)
 
1
 
 fam-
ily of integral type I membrane proteins (1). In addition to
the NGFR, the two TNFR and 4-1BB, other members of
this family include CD27, CD30, CD40, OX-40, and Fas
(2). Similar to other members of this family, 4-1BB can
provide either costimulatory signals leading to activation,
IL-2 production and enhanced proliferation and differenti-
ation, or death signals to T cells, depending on the state of
activation and stage of differentiation of the T cell (3–5).
The biochemical pathways utilized by the 4-1BB receptor
for conveying these activation signals have not yet been
elucidated. However, the cytoplasmic domain of murine
4-1BB contains the consensus sequence (Cys-X-Cys-Pro)
for binding p56
 
Lck
 
 and it has been shown that Lck can be
immunoprecipitated using mAbs to the 4-1BB receptor
(1). This observation suggests that 4-1BB may be linked to
the 
 
src
 
 tyrosine kinase family signaling pathway. Although
not expressed in resting T cells, 4-1BB mRNA can be de-
tected within 1.5 h of CD3/TCR or PMA/ionomycin
stimulation (6), followed by cell surface expression within
10 h of activation (our personal observation). Recently, a
high affinity ligand for 4-1BB (4-1BBL) was cloned and
the protein was shown to be a type II membrane protein of
the TNF family (7). Thus, like all of the other members of the
TNFR family, the ligand for 4-1BB is also a member of the
TNF family of molecules. 4-1BBL is expressed in low lev-
els on resting B cells and upregulated on activated B cells
and monocytes (7). Using 4-1BB fusion proteins or 4-1BB
transfected cell lines it has been shown that engagement of
 
1
 
Abbreviations used in this paper:
 
 4-1BBL, 4-1BB ligand; EU, endotoxin
units; FBS, fetal bovine serum; NGFR, nerve growth factor receptor; SN,
activated T cell supernatants.
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Amplification of CTL Activity Through the 4-1BB Receptor
 
4-1BBL on B cells provides them with an anti-
 
m
 
–depen-
dent costimulatory signal that amplifies B cell proliferation
(8). In addition to the high affinity ligand for 4-1BB, we
have found that murine 4-1BB binds to extracellular matrix
proteins (9). The biological significance of this observation
is presently under investigation.
Currently, all published studies addressing the functional
activities of the 4-1BB/4-1BBL system have been carried
out in vitro and have focused on costimulatory signals gen-
erated through the 4-1BB receptor on unseparated T cells.
In this study, we show that anti-4-1BB mAbs preferentially
activate CD8
 
1
 
 T cells both in vitro and in vivo, alter the ki-
netics of tyrosine phosphorylation as well as substrates and
markedly amplify the generation of antigen-specific CTL re-
sponses in vivo. In this regard, costimulation through 4-1BB
and CD28 are reciprocal in nature and complimentary to
one another by activating individually CD8
 
1
 
 and CD4
 
1
 
T cells, respectively. The results of our investigation also
suggest that anti-4-1BB mAbs and mAb derivatives may
have novel immunoregulatory properties that will prove
useful for the development of clinical reagents for the treat-
ment of chronic infectious diseases and cancer.
 
Materials and Methods
 
Construction of 4-1BB Fusion Proteins.
 
The murine 4-1BB–Ig
fusion constuct was generated in the following manner: DNA en-
coding the extracellular domain of murine 4-1BB (residues 22–185)
was generated by PCR using an upstream primer containing a KpnI
site (5
 
9
 
-CCGCGGGTACCCGTGCAGAACTCCTGTGATAA-
CTGT-3
 
9
 
) and a downstream primer containing a BamHI site
(5
 
9
 
-CCGCTACGTAGGATCCTGCAAGGAGTGCCCTCC-
TGG-3
 
9
 
). The murine 4-1BB DNA fragment was cloned in
frame into the CDM7(B
 
2
 
) vector that contains the CD5 signal
sequence, followed by a KpnI site and the human immunoglobu-
lin constant region preceded by a BamHI site.
The murine 4-1BBL–CD8 fusion construct was prepared as fol-
lows: DNA encoding the extracellular domain of murine 4-1BBL
(residues 104–309) was generated by PCR using an upstream
primer containing a BamHI site (5
 
9
 
-GCGGCGGATCCCCGC-
ACCGAGCCTCGGCCAGCG-3
 
9
 
) and a downstream primer
containing an XbaI site (5
 
9
 
-CGCTCTAGAGGATAGTTCTCA-
TTCCCATGG-3
 
9
 
). The murine 4-1BBL DNA fragment was
cloned in frame into the CDM7(B
 
2
 
) vector containing the extra-
cellular domain of CD8 followed by a BamHI site.
 
Generation and Characterization of mAbs.
 
Monoclonal anti-mouse
4-1BB mAbs were generated by immunizing Lewis rats with 4-1BB
fusion proteins prepared as described earlier (10). Using immune
spleen cells and the mouse myeloma X63-AG8.653 cell line as
fusion partner (11), rat–mouse hybridomas were generated and
selected using standard published techniques.
 
Biacore Analysis.
 
All studies were carried out on a Biacore in-
strument equipped with the Biacore 1000 upgrade kit (Pharmacia
Biosensor, Uppsala, Sweden). Experiments were carried out at
25
 
8
 
C using PBS, pH 7.4, containing 0.0005% surfactant P20
(Pharmacia Biosensor) as the running buffer. The carboxymethyl-
ated dextran matrix of research grade sensor chip CM5 was mod-
ified using the amine coupling kit as follows: equal volumes of 0.10
M NH
 
2
 
-hydroxysuccinimide and 0.40 M 
 
N
 
-ethyl-
 
N
 
9
 
-(3-dimethyl-
aminopropyl)carbodiimide  were mixed and injected to activate
 
the surface for 4 min. The receptor, a solution of 4-1BB–IgG in
10 mM sodium formate, pH 4.0, was injected for 4 min. Re-
maining active sites were reacted by the injection of 1 M ethanol-
amine for 5 min. Immobilization of 
 
z
 
1,000 RU of receptor was
achieved. Each of the antibodies and fusion protein was diluted to
67 nM in the running buffer and 100 
 
m
 
l was injected at a flow
rate of 5 
 
m
 
l/min, followed by running buffer alone to allow ob-
servation of the dissociation of bound protein. After each cycle,
the surface was regenerated by the injection of 1 M formic acidin,
0.15 M NaCl for 30 s. Association and dissociation rates for each
sensorgram were determined by curve fitting using BIAevalua-
tion 2.1 software. The affinity was calculated by dividing the dis-
sociation rate by the association rate. The association rates for two
antibodies, 1D8 and 21E5, were confirmed by the method of do-
ing a series of injections at concentrations ranging from 10 to 100
nM. BIAevaluation 2.1 was used to fit the data to the appropriate
model.
 
Purification of Proteins.
 
The 3B8 mAb (IgM) was affinity puri-
fied on an anti-
 
k
 
 chain (mAB RG7) column. All other mAbs
(IgG2a) were purified on protein G (Gammabind Plus; Pharmacia).
All antibodies were eluted with IgG elution buffer (Pierce Chem.
Co., Rockford, IL), neutralized immediately, dialyzed versus PBS,
and filter sterilized. Endotoxin levels in the purified antibodies
were less than 0.3 EU/mg, except for the 21E5 mAb (1.2 EU/mg)
and 5C12 (0.5 EU/mg). The negative control mAb, 6E9, was a
rat IgG2a antibody, reactive with human gp-39. The 4-1BBL–
CD8 (Lyt2a) fusion protein was affinity purified using an anti-
CD8 column (mAb 53.6). The protein was eluted with 40% pro-
pylene glycol, 60% 50 mM Tris, pH 7, with 1.25 M (NH
 
4
 
)
 
2
 
SO
 
4
 
.
 
T Cell Activation and FACS
 
Ò
 
 Analysis.
 
The D0-11-10 T cell
hybridoma was treated with 10 ng/ml PMA and 0.5 
 
m
 
g/ml iono-
mycin. The cells were cultured in RPMI 1640 with 10% fetal bo-
vine serum (FBS) and 1% penicillin and streptomycin solution
(GIBCO BRL, Gaithersburg, MD). The cells were subsequently
phenotyped by indirect immunofluorescence and FACS
 
Ò
 
 analysis
using a FACStar
 
Ò
 
 flow cytometer (Becton-Dickinson Immunocy-
tometry Systems, San Jose, CA) for 4-1BB expression. D0.11.10
cells express 4-1BB on the cell surface within 10 h of stimulation
and expression peaks between 12–14 h. To evaluate the ability of
the various anti–4-1BB mAbs to block ligand receptor binding,
activated D0-11-10 were incubated at 4
 
8
 
C, with 0.02% azide for
1 h with various concentrations of the anti–4-1BB mAbs then
purified 4-1BBL–CD8 fusion protein was added to a final con-
centration of 1 
 
m
 
g/ml and the incubation continued for 1 h. Cells
were then washed and ligand binding determined with phyco-
erythrin-conjugated 53.6 (anti-CD8) (Boehringer Mannheim).
 
Splenic T Cell Activation for Induction of 4-1BB Expression.
 
BALB/c splenic T cells were purified from unseparated cells by
treatment with anti-IA
 
d
 
 mAb (PharMingen) and anti-CD11b
(PharMingen) at 12 
 
m
 
g/ml each per 1 
 
3
 
 10
 
8
 
 spleen cells/ml fol-
lowed by incubation at 4
 
8
 
C for 20 min. The cells were washed
with PBS (2 
 
3
 
 50 ml) and resuspended at 2–4 
 
3
 
 10
 
8
 
/ml, fol-
lowed by the addition of 0.4 ml of magnetic beads coated with
goat anti–mouse IgG (Dynal)/2 ml of cell suspension. The cell
suspension was then incubated at 4
 
8
 
C on a rotator for 10 min, af-
ter which the cell volume was increased to 8 ml with PBS. Non–T
cells bound to the magnetic beads were removed using a mag-
netic field. The remaining cells were washed, resuspended to 2
ml, and again placed in a magnetic field to remove residual beads.
Washed T cells were then resuspended to 1 
 
3
 
 10
 
7
 
/ml in RPMI
1640 containing antibiotics and 10% FBS and phenotyped by
FACS
 
Ò
 
 for CD3 expression and found to be 
 
.
 
95% CD3
 
1
 
.
T cells were activated for varying periods of time up to 72 h by 
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adding hamster anti-CD3 (145.2C11, PharMingen) at 1 
 
m
 
g/ml
together with 0.5% non–T cells to the cultures and incubating at
37
 
8
 
C. In some cases, splenocytes were first activated and then the
non–T cells were removed as described above before using the
activated T cells.
 
T Cell Proliferation Assays.
 
BALB/c splenic T cells were pre-
pared as described earlier. CD4
 
1
 
 and CD8
 
1
 
 T cell subsets were
prepared by negative selection using anti-CD4 and anti-CD8
mAbs (PharMingen) and magnetic beads (Dynal). The protocol
followed was that supplied by the manufacturer. Unseparated T
cells or T cell subsets were cultured in 96-well flat-bottomed mi-
crotiter plates at a density of 1 
 
3
 
 10
 
5
 
/well in 200 
 
m
 
l of RPMI
1640 containing 10% FBS and 1% 
 
l
 
-glutamine and penicillin/
streptomycin (GIBCO BRL). In addition, cultures were supple-
mented with 0.5% non–T cells as a source of FcR
 
1
 
 cells used to
present mAbs to the T cells. Cultures were maintained at 37
 
8
 
C
for the indicated periods. During the final 12 h of culture the cells
were pulsed with 1 
 
m
 
Ci/well [
 
3
 
H]thymidine (NEN, Boston,
MA). All cultures were harvested and counted by liquid scintilla-
tion spectroscopy.
 
GVHD Experiments and CTL Assay.
 
GVHD was established
in 8- to 10-wk-old BDF
 
1
 
 (H-2
 
bd
 
) female mice by tail vein injection
of 1 
 
3
 
 10
 
7
 
 purified C57BL/6 (H-2
 
b
 
) T cells. Recipient mice re-
ceived at the time of T cell injection and again on days 2 and 4,
200 
 
m
 
g of anti-4-1BB mAb, an equivalent amount of isotyped-
matched negative control mAb (6E9), which is reactive with hu-
man gp-39, or PBS. On day 10, mice were killed and splenic sin-
gle cell suspensions prepared, and 2 
 
3
 
 10
 
4
 
 
 
51
 
Cr-labeled P815 cells
cultured in 200 
 
m
 
l of RPMI 1640 containing 10% FBS in 96-well
round-bottomed microtiter plates. In some instances, T cells were
first isolated and used as effectors in CTL assays. The plates were
spun at 1,000 rpm for 1 min before incubating at 37
 
8
 
C for 4 h.
After the incubation period, 100 
 
m
 
l of culture supernatant was
collected and counted in triplicate in a Packard Cobra 
 
g
 
 counter.
Specific 
 
51
 
Cr-release was calculated in percent using the formula:
sample release 2 spontaneous release/total release 2 spontaneous
release 3 100.
Western Blots. Cell lysates were prepared from 48-h anti-
CD3–activated BALB/c splenic T cells that had been fractionated
into CD41 and CD81 subsets after activation. Both subsets were
then restimulated with anti-CD3, anti–4-1BB, or a combination
of the two for the times indicated. The cells were then lysed in
1% NP-40 lysis buffer containing protease and phosphatase inhibi-
tors. Lysates containing 1 3 107 cells/ml were immunoprecipitated
overnight using 5 ml of rabbit anti–phosphotyrosine antibody
(Zymed Labs, San Francisco, CA) and 25 ml of protein G–Sepharose
beads (Pharmacia-Biotech, Uppsala, Sweden) at 48C. After extensive
washing of the beads, 50 ml of 23 sample buffer were added and
the mixture was heated to 1008C for 5 min. The samples were
then loaded on 4–20% density gradient gels and electrophoresed.
Gels were then electroblotted at 20 V overnight, blocked with
6% BSA/PBS, and blotted with a 1:5,000 dilution of AP-conju-
gated monoclonal anti-phosphotyrosine antibody 4G10 (UBI,
Lake Saranac, NY) overnight at 48C. Blots were washed three
times in PBS for 59/wash, one time in PBS–.002% Tween 20,
and one time in PBS before adding ECL reagents for 1 min, fol-
lowed by exposure to film.
Anti-4-1BB–induced Cytokine Production. Resting CD41 and
CD81 BALB/c splenic T cells (1 3 106/ml) were stimulated for
the indicated periods with anti-CD3 at 1 mg/ml with or without
10 mg/ml anti–4-1BB (3H3) or anti-CD28 (3N7). Culture su-
pernatants were collected and assayed by ELISA assay for IL-2,
IL-4, IL-10, and IFN-g.
Results
Generation of Anti–4-1BB mAbs. Using the published se-
quences for murine 4-1BB and 4-1BBL, we constructed fu-
sion proteins containing the extracellular domain of 4-1BB
and the COOH region of human IgG1 (9). 4-1BBL fusion
protein was constructed using the 4-1BBL extracellular do-
main fused with the NH2-terminal region of murine CD8
(data not shown). 4-1BB–Ig fusion protein was used to im-
munize rats in order to generate mAbs. More than a dozen
hybridomas having unique specificity for 4-1BB were se-
lected on the basis of ELISA binding assay on purified
4-1BB–Ig fusion protein, activated T cell reactivity, and
immunoprecipitation of a 36-kD protein (data not shown).
All of the mAbs were of the rat IgG2A isotype except for
3B8, which was found to be a rat IgM antibody. These
mAbs were then analyzed by surface plasmon resonance in
order to determine their association and dissociation rates as
well as their avidity for antigen (Table 1). We also deter-
mined the ability of all mAbs to block 4-1BB/4-1BBL
binding on activated, 4-1BB1, D0.11.10 cells. The results
for several of these mAbs is shown in Fig. 1. From this ex-
periment, it can be seen that there is considerable heteroge-
neity among the tested antibodies with respect to their ability
to block 4-1BBL binding. Through 4-1BB domain swap-
ping experiments we found that the 1D8 binding site was
located near the NH2-terminal end of the protein and away
from the ligand binding region of the molecule (data not
shown). All of the remaining antibodies bind at or near the
ligand binding site, including the IgM isotype mAb 3B8.
However, the low binding avidity of 3B8 presumably pre-
vents it from effectively blocking ligand binding to 4-1BB.
Costimulatory Properties of Anti–4-1BB Mabs. All of the
anti–4-1BB were tested for their ability to costimulate
T cell proliferation induced by the 145.2C11 hamster anti–
mouse CD3 mAb. Anti–4-1BB mAbs at 10 mg/ml were
added to T cell cultures in which anti-CD3 mAb was ti-
trated from 3–100 ng/ml. In Fig. 2, the results of a typical
experiment are shown for several selected mAbs. At a con-
Table 1. Plasmon Resonance Analysis of Anti–4-1BB mAb 
Binding to 4-1BB–Ig Fusion Protein
Antibody Isotype ka kd kd/ka
M21s21 s21 M
1D8 IgG2A 2.9 3 105 1.2 3 1024 4.14 3 10210
22B6 IgG2A 5.7 3 105 1.5 3 1024 2.63 3 10210
3H3 IgG2A 3.7 3 105 1.9 3 1024 5.14 3 10210
15B9 IgG2A 4.3 3 105 1.1 3 1024 2.56 3 10210
3E1 IgG2A 5.7 3 105 1.3 3 1025 2.28 3 10211
5C12 IgG2A 5.6 3 105 1.5 3 1024 2.68 3 10210
21E5 IgG2A 5.3 3 105 1.1 3 1024 1.99 3 10210
3B8 IgM 2.8 3 1025
4-1BB Ligand 1.83 3 105 2.13 3 1024 1.16 3 102950 Amplification of CTL Activity Through the 4-1BB Receptor
centration of 3 ng/ml of anti-CD3, anti–4-1BB mAbs en-
hanced the proliferative response from two- to eightfold
depending upon the specific mAb used. Anti–4-1BB mAbs
in the absence of anti-CD3 had no stimulatory effect on
proliferation of T cells (data not shown).
Costimulation of CD41 and CD81 T Cells via 4-1BB Re-
ceptor. 4-1BB expression on activated CD41 and CD81 T
cells occurs with the same kinetics and degree of expression
(data not shown). Although both subsets express 4-1BB at
equivalent levels it is not known whether the 4-1BB recep-
tor preferentially or differentially regulates the activation or
proliferative potential of either subset. To test this possibil-
ity, we isolated highly purified populations of resting splenic
BALB/c CD41 or CD81 T cells (.98% purity) by nega-
tive selection procedures described earlier. T cell subsets
were then incubated with soluble 145.2C11 mAb in a
range of 10–1,000 ng/ml 6 10 mg/ml anti–4-1BB mAb
for 3 d in the presence of 0.5% APC. Proliferation was
monitored by [3H]thymidine incorporation during the final
12 h of culture. In Fig. 3 A we show the results of one of
four proliferation experiments carried out on isolated
CD41 T cells or CD81 T cells obtained from the same
group of mice. From these experiments, it is clear that co-
stimulation of CD41 T cells with anti–4-1BB mAbs such as
3E1 and 3H3 led to a two- to threefold enhancement of
anti-CD3–induced proliferation, whereas others such as
1D8, a nonligand-blocking antibody, had little effect upon
T cell proliferation. mAb 6E9 is an isotype-matched nega-
tive control that is reactive with human gp-39. In contrast,
the same set of antibodies markedly enhanced CD81 T cell
proliferative responses by lowering the threshold of anti-
CD3 concentration 10- (1D8) to 100-fold (3H3) and in-
creased the incorporation of [3H]thymidine z100-fold.
4-1BB Initiates Proliferative Signals to T Cells. Because the
most efficient anti–4-1BB antibodies capable of inducing
T cell proliferation happen to be those that effectively block
ligand–receptor binding, we questioned whether or not
antibody-mediated proliferation was initiated by the con-
veyance of a positive signal to the T cell, or inhibition of a
negative signal provided by 4-1BBL binding to its receptor.
To address this question, we stimulated T cell subsets as
well as unseparated T cells in the presence of APCs (5%)
with anti-CD3 mAb with or without soluble 4-1BB–Ig fu-
sion protein. As shown in Fig. 3 B, the inclusion of 4-1BBL
into all T cell cultures diminished the proliferative re-
sponses initiated by anti-CD3 stimulation. Also of note was
the observation that CD81 T cells were the most adversely
affected by this treatment. These results support our find-
ings that anti–4-1BB mAbs preferentially activate CD81 T
cells.
CD28 and 4-1BB Preferentially Costimulate Reciprocal T Cell
Subsets. As a result of our observation that 4-1BB costimu-
lation is markedly more effective in CD81 T cells than CD41
T cells, we compared these findings to those obtained after
costimulation of each subset with anti-CD28 (3N7) mAbs.
In Fig. 4 we show a typical experiment in which the kinet-
ics of costimulation were studied on CD41 T cells or
CD81 T cells using antibodies to either 4-1BB (3H3 and
3E1) or CD28 (3N7). The results of this experiment clearly
demonstrate that 4-1BB and CD28 molecules preferentially
activate CD81 and CD41 T cell subsets, respectively, and
that 4-1BB costimulation peaks at 48 h.
Induction of Protein Tyrosine Phosphorylation by Anti-4-1BB
mAb. In light of the observed selective effect that anti-4-1BB
mAbs had on CD81 T cell proliferation, we analyzed the
ability to 3E1 (or 3H3; data not shown) to influence early
signal transduction events in purified populations of 48-h
anti-CD3–activated CD41 and CD81 T cells. After a 15-
min incubation with 3E1, 145.2C11, or both (each mAb at
10 ng/ml) at room temperature, the cells were placed in a
water bath equilibrated to 378C and incubated for the indi-
cated times after the addition of 50 ng/ml of a mouse anti–
rat mAb, RG7, that cross-reacts with hamster mAb. When
both anti-CD3 and anti–4-1BB were added together, the
concentration of RG7 was doubled. In Fig. 5 A and Fig. 5
B, the results of a typical experiment are shown for CD41
and CD81 T cells, respectively. The most notable feature
Figure 2. Anti–4-1BB mAbs
costimulate anti-CD3–induced
T cell proliferation. BALB/c T
cells were cultured for 72 h at 2 3
105/well in 96-well flat-bottomed
microtiter plates with the indicated
concentrations of 145.2C11 with
PBS control (-d-) or with the
following: anti–4-1BB mAbs
15B9 (-h-), 1D8 (--s--), 21E5
(--m--), 3B8 (...d...), 3H3 (.-r.-),
and 3E1 (..-,-..), each at 10 mg/
ml. Results are expressed as the
mean 6 SD of triplicate wells.
Figure 1. Anti–4-1BB mAbs
block 4-1BBL binding to acti-
vated DO.11.10 T cells. T cells
were activated as described above.
Cells were then incubated with
dilutions of anti–4-1BB mAbs
for 30 min before the addition of
4-1BBL–CD8 fusion protein at 1
mg/ml and the cells were incu-
bated for an additional 30 min.
Cells were washed twice in PBS,
incubated with PE-conjugated
anti-CD8 mAb, and assayed by
FACSÒ for ligand binding.51 Shuford et al.
of this experiment is that previously activated CD81 T cells
are more responsive to anti-CD3 stimulation when com-
pared with CD41 T cells. This is not due to differential ex-
pression levels of CD3 within the two populations (our
personal observations). Apart from the fact that CD81 T
cells were more activated than CD41 T cells as judged by
both the number and intensity of phosphoprotein bands on
the gel, it is noteworthy that within the CD81 subset, signals
delivered by anti-CD3 and anti–4-1BB are virtually indis-
tinguishable from each other in terms of phosphotyrosine
species observed, intensity of phosphorylation, as well as
the kinetics of phosphorylation. In contrast, this is less true
of the CD41 T cell population. In both figures, arrows de-
lineate proteins undergoing significant changes in phosphor-
ylation. The band with the slowest mobility also appears to
undergo serine/threonine phosphorylation since its mobility
is further retarded after 4-1BB cross-linking. Costimulation
of CD81 T cells through CD3 and 4-1BB receptors alters
the magnitude, kinetics, and profile of phosphoproteins
compared with stimulation with either one alone. It should
be pointed out that the data in both figures were generated
from equivalent cell numbers from the same mice and that
the number of cell equivalents (lysates) used/lane were iden-
tical in both experiments, as were the exposure times used in
generating the ECL Western blots.
Anti–4-1BB mAbs Enhance CTL Generation In Vivo.
Because anti–4-1BB mAbs had such a profound effect
upon the signaling and proliferative responses of CD81
T cells, we questioned the importance of 4-1BB signaling
in the generation of T cell effector functions such as cyto-
toxic T cell responses. Therefore, we measured the ability
of a panel of anti–4-1BB mAbs of the IgG2A isotype in-
cluding blocking (3E1, 22B6, and 3H3) and nonblocking
(1D8) mAbs to affect either the generation of CTL during
acute GVHD or in a murine cardiac allograft or MHC mis-
matched skin transplant model. To generate acute GVHD
and assay CTL activity, splenic T cells were isolated from
BDF1 (H-2db) mice 10 d after intravenous injection of 1–5 3
107 C57BL/6 (H-2b) splenocytes. Spleens removed from
1D8 and 22B6-treated GVHD mice were enlarged 3–5
times the size of normal spleens. Mice that received the iso-
type-matched negative control mAb 6E9 had spleens that
were 2–3 times the size of normal mice. When assayed for
CTL activity, 1D8 and 22B6, each known to bind to a dif-
ferent region of the 4-1BB molecule, enhanced CTL activ-
ity by nearly fourfold over that observed in control GVHD
animals (Fig. 6 A). The powerful effect of anti–4-1BB
mAbs on the enhanced development of CTL activity is fur-
ther demonstrated in Fig. 6 B, which shows a marked re-
duction in the number of total viable splenocytes retrieved
from mice treated with these antibodies. In addition, phe-
notypic analysis of splenocytes revealed that the percentage
of CD81 T cells increased to 30% of the total cell number
in mice treated with anti–4-1BB mAbs (Fig. 6 C), whereas
GVHD mice injected with 6E9, the isotyped-matched non-
binding control or those receiving no antibody had 5–8%
CD81 T cells. Epitope mapping studies of anti–4-1BB
mAbs using 4-1BB fusion proteins in which domain swap-
ping was carried out demonstrated that the 1D8 mAb was
unique in that it bound to the membrane proximal region
of the extracellular domain of the 4-1BB molecule not in-
volved in 4-1BBL binding.
Anti–4-1BB mAbs Enhance Cardiac Allograft Rejection. 3E1
was chosen to study for its ability to affect cardiac allograft
Figure 3. (A) Anti–4-1BB mAbs differentially co-
stimulate in vitro proliferation of CD41 and CD81 T
cell subsets. Purified resting CD41 or CD81 BALB/c
splenic T cells were cultured for 72 h in 96-well mi-
crotiter plates at 1 3 105/well with 0.5% APC 6 anti–
4-1BB mAb at 10 mg/ml and the indicated concentra-
tion of anti-CD3 mAb. Cells were pulsed with 0.5
mCi/well [3H]thymidine for the final 12 h of culture,
harvested, and counted by liquid scintillation spectros-
copy. (B) 4-1BB–Ig fusion protein inhibits anti-CD3–
induced T cell proliferation. CD41 and CD81 T cells
with APC were stimulated with anti-CD3 mAb at 300
ng/ml in the absence or presence of soluble 4-1BB–Ig fusion protein. Cells were pulsed during the final 12 h of culture with [3H]thymidine, harvested,
and counted by liquid scintillation spectroscopy.52 Amplification of CTL Activity Through the 4-1BB Receptor
rejection in mice because its avidity was the highest of all of
the anti–4-1BB mAbs that we generated and it most effi-
ciently blocked 4-1BBL binding to its receptor. The results
of this experiment clearly demonstrated that the binding of
anti–4-1BB mAb to activated T cells in mice receiving
heart allografts led to the rapid rejection of the allograft (3
of 5 by day 7–8) compared with the control group (3 of 4
by day 10). Similar results were obtained in MHC-mis-
matched skin transplant experiments in mice using 3E1,
3H3, or 1D8 (data not shown).
Anti–4-1BB Costimulation Induces IFN-g Production in CD81
T Cells. To understand better how 4-1BB–mediated signals
amplify CTL activity, we analyzed the kinetics of IL-2, IL-4,
IL-10, and IFN-g production by resting CD41 and CD81
or unseparated T cells stimulated with anti-CD3 or anti-
CD3 together with anti-CD28 or anti–4-1BB. In Fig. 7, it
can be seen that CD28-mediated costimulation signifi-
cantly amplified the production of all four lymphokines by
CD41 and unseparated T cells but had little effect on
CD81 T cells. In contrast, 4-1BB–mediated costimulation
had no significant effect upon the CD41 T cell subset with
perhaps IFN-g being the exception. On the other hand,
4-1BB–mediated costimulation markedly enhanced the pro-
duction of IFN-g by CD81 T cells as well as in unseparated
T cells. This feature appeared to be a general characteristic
of anti–4-1BB mAbs, as several of them were tested and
found to have the same properties (data not shown).
Discussion
In this study, we have confirmed that anti–4-1BB mAb-
induced cross-linking of the 4-1BB receptor in vitro pro-
vides a potent costimulatory effect on anti-CD3–induced
polyclonal T cell proliferation. However, we also found
that 4-1BB–mediated proliferation was highly biased to-
ward the CD81 subset of T cells. For instance, the addition
of anti-4-1BB mAb 3H3 (10 mg/ml) reduced the threshold
of anti-CD3 from 1,000 ng/ml to 10 ng/ml and increased
the absolute value of cpm of [3H]thymidine incorporated
(Fig. 2 B) by CD81 T cells 100-fold. In contrast, signaling
through the 4-1BB receptor on CD41 T cells resulted in a
fourfold increase in proliferative capacity (Fig. 2 A). In
both cases, 4-1BB–mediated costimulation was maximal at
48 h. Stimulation of either population with varying doses
of anti-CD3 alone demonstrated that these two populations
are near-equivalent in their ability to respond to CD3-medi-
ated proliferative signals, with CD41 T cells being some-
what more responsive in these experiments. Furthermore,
in contrast with 4-1BB, CD28-mediated costimulation was
highly biased toward CD41 T cell activation (Fig. 5) and
optimal activation occurred at 72 h. Thus, there is a recip-
rocal relationship of costimulation through these two re-
ceptor systems with regard to T cell subset proliferation.
The ability of anti–4-1BB mAbs to enhance T cell acti-
vation was found to be more dependent upon epitope rec-
ognition than antibody isotype or antibody avidity, because
both antibodies of the IgM and IgG2A isotype were equally
effective as costimulators, and within the IgG2A isotype, an-
tibodies having similar avidity varied markedly with respect
to their biological activity. For instance, all of the antibod-
ies, regardless of avidity or isotype, that bound near or at
Figure 4. Anti-CD28 (3N7) and anti-4-1BB (3H3 and 3E1) mAbs co-
stimulate opposite T cell subsets. Purified CD41 and CD81 resting T cells
were costimulated with either anti-CD3 and anti-CD28 or anti-CD3 and
anti–4-1BB mAbs for 24, 48, or 72 h. Cultures were pulsed with [3H]thy-
midine for the final 12 h of culture.53 Shuford et al.
the ligand binding site were most effective at inducing co-
stimulation. This observation led us to question whether or
not enhanced proliferation induced by these reagents was a
consequence of their ability to block a negative prolifera-
tion signal transmitted by 4-1BBL binding to the 4-1BB
receptor. This was not found to be the case (Fig. 3 B).
Rather, our data support the view that cross-linking the
4-1BB receptor on an activated T cell transmits a positive
activation signal to the cell. This notion is further sup-
ported by the observation that 4-1BB cross-linking on acti-
vated CD81 T cells led to rapid tyrosine phosphorylation
of multiple substrates and that the pattern of phosphoryla-
tion was nearly identical to anti-CD3–induced protein ty-
rosine phosphorylation. This finding suggests that the 4-1BB
receptor on CD81 T cells may be structurally or function-
ally coupled to the TCR of these cells.
Figure 5. Cross-linking 4-1BB
initiates distinct patterns and ki-
netics of protein tyrosine phos-
phorylation in CD41 and CD81
T cell subsets. BALB/c spleno-
cytes were activated as described
earlier. CD41 (A) and CD81 (B)
subsets were incubated with 10
ng/ml of anti-CD3, anti–4-1BB
(3E1), or both at 10 ng/ml each.
After 15-min incubation at room
temperature, the cells were
equilibrated to 378C and cross-
linked with 50 ng/ml of RG7, a
mouse anti–rat IgG that cross-
reacts with hamster IgG. Where
both anti-CD3 and anti-4-1BB
were added together, RG7 was
added at 100 ng/ml. Untreated
(lane 1), 1 min (lane 2), 3 min
(lane 3), 9 min (lane 4).
Figure 6. (A) Anti–4-1BB mAbs en-
hance or inhibit in vivo generation of
CTL responses during GVHD responses.
GVHD was established by intravenous in-
jection of 5 3 107 C57BL/6 (H-2b) sple-
nocytes into DBA/2 (H-2bd) mice as de-
scribed in the Materials and Methods.
The administration of mAbs was carried
out as described earlier. On day 10,
spleens were collected from GVHD mice
and single cell suspensions prepared. CTL
activity in this population was measured
directly by assaying CTL-mediated killing
of 51Cr-labeled P815 cells. (B) Total sple-
nocyte levels are markedly reduced in
mice receiving anti–4-1BB mAbs. The
total number of viable splenocytes ob-
tained from groups of three spleens pooled
from each treatment group was assessed
by microscopy and trypan blue exclusion.
(C) Percentages of viable CD81 T cells
were determined for each treatment group
using FITC-conjugated anti-murine CD8
mAb (PharMingen) and flow cytometry.54 Amplification of CTL Activity Through the 4-1BB Receptor
In light of the fact that CD81 T cells preferentially re-
spond to 4-1BB costimulation, we assessed the effects of
several anti-4-1BB mAbs in vivo. For these studies, we
chose to examine the effects of anti-4-1BB mAbs on CTL
development as this activity represents a major function of
the CD81 T cell subset. To facilitate these studies, we chose
acute GVHD, cardiac allograft, and MHC-mismatched skin
transplantation as murine models for our studies. The ability
of anti-4-1BB mAbs to enhance GVHD (Fig. 6 A) leading
to marked depletion of host splenocytes (Fig. 6 B) appears to
be the result of preferential costimulation and amplification
of CD81 T cells in vivo (Fig. 6 C). In contrast, the per-
centage of CD41 T cells did not change (data not shown).
In cardiac allograft (Fig. 7) and skin transplant studies (data
not shown) we found that transplants were rejected faster
in mice treated with any of a variety of anti-4-1BB mAbs
than what was observed in control mice injected with the
6E9 mAb. We also found certain functional differences in
this system. For example, certain mAbs, such as 22B6 and
1D8, were poor inducers of proliferation, whereas mAbs
such as 3E1 and 3H3 were strong inducers of proliferation.
Nevertheless, all were equally effective at enhancing GVHD
in mice and in rejecting MHC-mismatched skin transplants
(data not shown). This suggests that the induction of CD81
T cell proliferation was not critical to the observed func-
tional effects in these systems. To explore further this issue,
we examined lymphokine production by CD41 and CD81
T cells or unseparated T cells costimulated with anti-CD3
alone or via costimulation with either anti-4-1BB or anti-
CD28 over a 96-h time course. The results of this experi-
ment demonstrated that anti-4-1BB costimulation had a
profound effect upon the upregulation of IFN-g produc-
tion by CD81 T cells but had little or no effect upon IL-2,
IL-4, or IL-10 production in either subset. In contrast,
anti-CD28–mediated costimulation had only a slight effect
upon IFN-g production by either subset. In contrast, anti-
CD28 costimulation markedly enhanced IL-2, IL-4, and
IL-10 production in CD41 T cells. When unseparated
T cells were activated as described above, the only notable
difference was the level of IFN-g produced after anti–4-1BB
costimulation. Allowing that z30–35% of these cells were
CD81, on a cell by cell basis, CD81 T cells in these cul-
tures produced lower (z50%) levels of IFN-g, which was
probably caused by inhibition of Th1 cytokine production
by IL-4 and IL-10.
From these studies, it would appear that 4-1BB/4-1BBL
differs from other previously defined receptor–ligand sys-
tems known to be important for costimulation of T cells in
that its primary effect appears to be the regulation of CD81
T cell activation. In contrast, other systems such as CD28–
Figure 7. Costimulation of CD81 T cells with anti-4-1BB but not anti-CD28 leads to IFN-g production. Unseparated and CD41 or CD81 resting T
cells were stimulated with anti-CD3 (d) or anti-CD3 and either anti-CD28 (j) or the anti–4-1BB mAb 3H3 (m). Activated T cell culture SN were col-
lected at 24, 48, 72, and 96 h and assayed by ELISA for IL-2, IL-4, IL-10, and IFN-g.55 Shuford et al.
CD80/CD86, CD27/CD27L, or gp39/CD40 primarily
affect the function of CD41 T cells. Finally, the increase in
amplitude of the CTL response during GVHD, cardiac al-
lograft, and skin rejection is not just limited to these forms
of alloantigenic stimulation; we have also observed the
same type of phenomena in mice injected with either non-
metastatic or highly metastatic, poorly immunogenic tu-
mors (manuscript in preparation). Under these conditions,
the administration of anti–4-1BB promoted rejection of
large established tumors and markedly enhanced animal
survival. Taken together, these observations point to a po-
tential therapeutic role for this receptor in the management
of cancer and chronic infectious diseases.
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